Matinas BioPharma partners with Resilience to explore oral nucleic acid delivery via LNC platform

Matinas BioPharma Holdings, Inc.

Material Transfer and Evaluation Agreement with National Resilience for oral delivery of nucleic acids.
Research program includes design, formulation, optimization, and in vitro/in vivo testing of nucleic acids with LNC platform.
Collaboration is distinct from ongoing work with BioNTech, allowing simultaneous platform development.
No financial terms disclosed; partnership aims to demonstrate LNC platform capabilities.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.